Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO 2017 Congress

Sep 20, 2017
4:30 PM ET




Stock Quote

NASDAQ: ARGS
0.15
- 0.01 (-7.24%)

Day High:
0.16

Day Low:
0.14

Volume:
4,221,140

3:59 PM ET on Dec 12, 2017
Delayed at least 20 minutes.

Tweets